HPK1 kinase inhibitor: a sufficient approach to target HPK1 to modulate T cell activation in cancer immunotherapy compared with degraders
2025 · Frontiers in Immunology · 3 citations
https://doi.org/10.3389/fimmu.2025.1449106
S
Sanjia Xu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
0
Papers
0
Citations
Sanjia Xu is an academic researcher.
ORCID: 0000-0002-3411-5151Papers by this author
worksChat about Author
Papers
Chat
Click to start Chat